1. Discovery, identification and mitigation of isobaric sulfate metabolite interference to a phosphate prodrug in LC–MS/MS bioanalysis: Critical role of method development in ensuring assay quality.
- Author
-
Yuan, Long and Ji, Qin C.
- Subjects
- *
DRUG development , *PHOSPHATES , *PRODRUGS , *DRUG metabolism , *BIOLOGICAL assay , *ISOBARIC processes , *THERAPEUTICS - Abstract
Metabolite interferences represent a major risk of inaccurate quantification when using LC–MS/MS bioanalytical assays. During LC–MS/MS bioanalysis of BMS-919194, a phosphate ester prodrug, in plasma samples from rat and monkey GLP toxicology studies, an unknown peak was detected in the MRM channel of the prodrug. This peak was not observed in previous discovery toxicology studies, in which a fast gradient LC–MS/MS method was used. We found out that this unknown peak would co-elute with the prodrug peak when the discovery method was used, therefore, causing significant overestimation of the exposure of the prodrug in the discovery toxicology studies. To understand the nature of this interfering peak and its impact to bioanalytical assay, we further investigated its formation and identification. The interfering compound and the prodrug were found to be isobaric and to have the same major product ions in electrospray ionization positive mode, thus, could not be differentiated using a triple quadrupole mass spectrometer. By using high-resolution mass spectrometry (HRMS), the interfering metabolite was successfully identified to be an isobaric sulfate metabolite of BMS-919194. To the best of our knowledge, this is the first report that a phosphate prodrug was metabolized in vivo to an isobaric sulfate metabolite, and this metabolite caused significant interference to the analysis of the prodrug. This work demonstrated the presence of the interference risk from isobaric sulfate metabolites to the bioanalysis of phosphate prodrugs in real samples. It is critical to evaluate and mitigate potential metabolite interferences during method development, therefore, minimize the related bioanalytical risks and ensure assay quality. Our work also showed the unique advantages of HRMS in identifying potential metabolite interference during LC–MS/MS bioanalysis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF